Scryb Inc. Forum: Community User: Philipp85

Clark Kent???

ChroMedX Corp. Expands Executive Team;Lahav Gil Appointed CEO and Director   January 05, 2018 – ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointments of MedTech visionary Lahav Gil as Chief Executive Officer and W. Clark Kent as President of the Company. Both have also been appointed to the Company’s board of directors.   Mr. Gil joins ChroMedX as the founder and former CEO of the innovative Toronto-based medical device industrial design and productization organization, Kangaroo Group (ISO 13485). Lahav founded the company in 2003 and evolved it into a full-spectrum outsourcing platform for Medical Device innovation, engineering, design, productization, RA submissions and contract manufacturing, contributing to many product launches in the Canadian and international MedTech industry. Kangaroo was acquired by full service medical device design company Starfish Medical in April of 2017.   “Lahav’s achievements speak for themselves but his energy, vision and passion for design and development is something truly remarkable.” said Gerard Edwards, Executive Chairman, ChroMedX Corp. “This appointment is an exciting milestone in a plan that the board of directors have been working on for quite sometime. We are proud to appoint Lahav as CEO and welcome him to the board of directors.”   Lahav is well known in the community for his strong team building abilities and emphasis on innovation culture, as well as his track record as a MedTech entrepreneur, design-driven innovator, and business leader.    “With the HemoPalm, ChroMedx is well positioned to bring a remarkable and critically needed product to market.” said Lahav Gil, CEO & Director, ChroMedX Corp. “Successful commercializing of a medical device relies on a deep and profound understanding of the problems that you are trying to solve at all levels of the product and business offering. Critically understanding the requirements of all the stakeholders including those leading to a strategic acquisition are key to this success, as well as designing for frictionless adoption models, a superior user experience, and a robust supply chain. It is essential to build a team and corporate culture that intuitively and strategically understands these concepts and loves working together on meaningful innovation and I am very excited to join ChroMedX and lead this process.”   W. Clark Kent has been appointed President and joined the ChroMedX board of directors. Clark is a capital markets professional with extensive experience leading corporate development and finance initiatives in the life sciences, technology and natural resource industries. For over a decade he has advised emerging companies on strategic planning, finance and recruitment in the North American and international marketplace.   “As a long-time supporter and consultant Clark has been instrumental in the advancement of ChroMedX and the HemoPalm technology.” said Gerard Edwards, Executive Chairman, ChroMedX Corp. “Clark has most recently been responsible for the Company’s partnership with DxEconomix and introduction to Lahav Gil. We are very pleased to now welcome him as a director and fulltime member of the team as ChroMedX President.”   With the appointments of Mr. Gil and Mr. Kent, Ash Kaushal will step down from his President, CEO and Director roles. Mr. Kaushal joined the Company as President and CEO in July 2016 after serving as a key consultant since the Company’s inception. The ChroMedX board of directors would like to thank Ash for his contributions and leadership in 2017. Mr. Kaushal will continue to work with the Company on a consulting basis.   With these appointments ChroMedX has increased its board to 6 directors. Further information on the Company’s executive team, board of directors and key advisors can be found at www.chromedx.com   About Lahav Gil   Lahav is the founder and former CEO of the Toronto based Kangaroo Group, which he built into a national brand and recently sold to Starfish Medical of Vancouver Island. He is passionate about meaning, loves Innovation Culture, Values-Based Leadership, transparency & awareness.    Lahav has deep experience in Medtech product development and business. He has founded/co-founded 6 companies and has accompanied many Canadian start-ups on their journey from napkin to launch, critically contributing to their investability, clinical and market readiness. He has contributed to over 200 technology product launches and to game-changing innovations for companies such as: IMRIS, FIO, fSona, Cellaegis, XOR, Ultrasonix, Exact Imaging, Sciex, and others.   For almost 3 decades, he has been involved with tech-innovation, entrepreneurship, and start-up companies, starting in Israel’s bustling innovation climate of the 80's. During the late 90's Lahav integrated into the Canadian innovation scene, leading Industrial Design projects and corporate-wide iD strategy for Creo/Kodak in Vancouver, where he first got a taste of the crucial role of culture in business. In 2003 he founded Kangaroo Design, which he evolved into the Kangaroo Group (ISO 13485), a full-spectrum outsourcing platform for Medical Devices innovation, engineering, design, productization, RA submissions and contract manufacturing.   Under his leadership, Kangaroo supplied services, infrastructure, and incubation partnerships to Canadian Medtech startups and entrepreneurs for over 15 years. During this time, Lahav’s main focus was building Kangaroo as a platform alongside spin-ins, spin-outs & incubation-investments.   Recent News   ChroMedX most recently announced the signing of a definitive agreement with diagnostics marketing experts DxEconomix to lead initiatives relating to potential high-value transactions. Further information can be found on the Company’s website.   Website   Investors and individuals interested in keeping abreast of latest news and updates can subscribe on the Home and News pages on the Company's website at www.ChroMedX.com

Wir sehen hier bald noch andere Kurse!

Ich hoffe es, dass Chromedx seinen Weg macht. Bin leider viel zu hoch rein. Ich hoffe die 0,60 sind bald wieder da. Was meint ihr? Ich glaube aber eher, dass der nächste Sprung bei einer Meldung kommt fda Zulassung beantragt oder so....

Das stimmt! Chromedx wird seinen weg gehen. Bin überzeugt von dem produkt

@Poseidon ja aber viele verstehen nicht das die BaFin nur eine Mafia ist! Die sollen sich um ihren eigenen scheiss kümmern

Oben bzw. hier der Link, lest den vollständigen Artikel, ist nur ein Auszug! https://www.bullvestorbb.com/kolumne-danke-bafin-oder-wie-man-mit-einem-satz-anlegervermoegen-vernichtet-und-leerverkaeufer-reich-macht-2/amp/

Alter Hut !

Seit Mitte Oktober 2014 schreibe ich regelmäßig über das Unternehmen ChroMedx Corp. (WKN: A12B6G). Als ich zum ersten Mal von der Story hörte, war ich sofort von der Story angetan, denn wenn ein kleines Unternehmen ein Gerät entwickelt, das laut den Spezifikationen besser ist, als alles, was sich auf dem Markt befindet, dann finde ich das schon bemerkenswert. Die Zusammenarbeit mit einer anerkannten Universität, in diesem Fall der Mac Master Uni in Toronto, wertete ich als Pluspunkt, denn dies hilft einem Startup wie ChroMedX immens an Kosten zu sparen. Die ersten Besprechungen erfolgen bei einem Preis von 0,13 EUR. Ja, ich bekam und bekomme Marketing-Budget vom Unternehmen bezahlt, um die Story des Unternehmens der breiten Masse der interessierten Anleger zuzuführen, die dann, wenn die Leser meiner Publikationen die Story genau so gut finden wie ich, die Aktie kaufen, oder auch nicht. Mein dahingehender Interessenkonflikt wird in meinem Disclaimer wie folgt ausgeführt: “Ein weiterer Interessenskonflikt ist auch dahingegeben, dass die beschriebenen Unternehmen direkt oder indirekt auch Kunden der bullVestor Medien GmbH sind, waren oder in Zukunft sein werden.” Dieser Disclaimer ist sowohl auf meiner Homepage, als auch in jedem meiner Newsletter zu finden. Im Newsletter selbst weise ich auch eingangs explizit darauf hin, dass man den den Disclaimer unbedingt beachten sollte. Also sollte eigentlich jedermann wissen, dass ich Marketing-Budget vom Unternehmen erhalte und zweitens Aktien des Unternehmens halte. Auf diesen Umstand weise ich wie folgt hin: “…möchten wir darauf hinweisen, dass Mitarbeiter, Autoren, Auftraggeber sowie nahestehende Personen oben genannte Aktien halten und somit ein Interessenskonflikt besteht.” Gestern, am Donnerstag, den 7.12.2017 um 14:45 veröffentlichte die BaFin dann folgende Meldung: Da ich als einziger über die Aktie berichtet habe und meine Interessenkonflikte nachweislich immer ausweise, überlegte ich, ob ich mich möglicherweise missverständlich über das Unternehmen geäußert habe. Aber nein, die Zahlen stimmen, die Leute stimmen und auch alles andere trifft zu 100% zu. Wo ist das Problem?

https://www.bullvestorbb.com/kolumne-danke-bafin-oder-wie-man-mit-einem-satz-anlegervermoegen-vernichtet-und-leerverkaeufer-reich-macht-2/amp/

Guten Morgen und ein gutes neues Jahr wünsche ich euch. Dieses hat für chromedx ja super begonnen. ;)

super news es wird noch zum Miliarden geschäft.

Sehr gut, so kann es weiter gehen

Hört sich sehr geplant an...wird uns n. m. M. noch sehr Freude machen...abwarten.

anuary 03, 2018 – ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to report on the signing of a definitive agreement with diagnostic marketing experts DxEconomix Inc. (DxEx) to conduct a high value transaction for the Company.   In August 2017 ChroMedX retained the consulting company for an evaluation of the HemoPalm Analyzer’s product viability, value offering, and market potential. Following an initial 90-day due diligence term ChroMedX accepted a proposal from DxEx and entered into a binding Letter-of-Intent stipulating a 60-day period for the companies to form and execute a definitive agreement. The definitive agreement has now been finalized and signed by both parties.

Ja nur weil einige billig einsteigen wollten! Aber die bringen demnächst bestimmt eine Klarstellung bzgl. BaFin und FDA-Zulassung